Citation
Seshasayee, Dhaya, et al. "In Vivo Blockade of OX40 Ligand Inhibits Thymic Stromal Lymphopoietin Driven Atopic Inflammation." The Journal of Clinical Investigation, vol. 117, no. 12, 2007, pp. 3868-78.
Seshasayee D, Lee WP, Zhou M, et al. In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. J Clin Invest. 2007;117(12):3868-78.
Seshasayee, D., Lee, W. P., Zhou, M., Shu, J., Suto, E., Zhang, J., Diehl, L., Austin, C. D., Meng, Y. G., Tan, M., Bullens, S. L., Seeber, S., Fuentes, M. E., Labrijn, A. F., Graus, Y. M., Miller, L. A., Schelegle, E. S., Hyde, D. M., Wu, L. C., ... Martin, F. (2007). In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. The Journal of Clinical Investigation, 117(12), 3868-78.
Seshasayee D, et al. In Vivo Blockade of OX40 Ligand Inhibits Thymic Stromal Lymphopoietin Driven Atopic Inflammation. J Clin Invest. 2007;117(12):3868-78. PubMed PMID: 18060034.
TY - JOUR
T1 - In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation.
AU - Seshasayee,Dhaya,
AU - Lee,Wyne P,
AU - Zhou,Meijuan,
AU - Shu,Jean,
AU - Suto,Eric,
AU - Zhang,Juan,
AU - Diehl,Laurie,
AU - Austin,Cary D,
AU - Meng,Y Gloria,
AU - Tan,Martha,
AU - Bullens,Sherron L,
AU - Seeber,Stefan,
AU - Fuentes,Maria E,
AU - Labrijn,Aran F,
AU - Graus,Yvo M F,
AU - Miller,Lisa A,
AU - Schelegle,Edward S,
AU - Hyde,Dallas M,
AU - Wu,Lawren C,
AU - Hymowitz,Sarah G,
AU - Martin,Flavius,
PY - 2007/08/09/received
PY - 2007/09/26/accepted
PY - 2007/12/7/pubmed
PY - 2008/2/13/medline
PY - 2007/12/7/entrez
SP - 3868
EP - 78
JF - The Journal of clinical investigation
JO - J Clin Invest
VL - 117
IS - 12
N2 - Thymic stromal lymphopoietin (TSLP) potently induces deregulation of Th2 responses, a hallmark feature of allergic inflammatory diseases such as asthma, atopic dermatitis, and allergic rhinitis. However, direct downstream in vivo mediators in the TSLP-induced atopic immune cascade have not been identified. In our current study, we have shown that OX40 ligand (OX40L) is a critical in vivo mediator of TSLP-mediated Th2 responses. Treating mice with OX40L-blocking antibodies substantially inhibited immune responses induced by TSLP in the lung and skin, including Th2 inflammatory cell infiltration, cytokine secretion, and IgE production. OX40L-blocking antibodies also inhibited antigen-driven Th2 inflammation in mouse and nonhuman primate models of asthma. This treatment resulted in both blockade of the OX40-OX40L receptor-ligand interaction and depletion of OX40L-positive cells. The use of a blocking, OX40L-specific mAb thus presents a promising strategy for the treatment of allergic diseases associated with pathologic Th2 immune responses.
SN - 0021-9738
UR - https://www.unboundmedicine.com/medline/citation/18060034/In_vivo_blockade_of_OX40_ligand_inhibits_thymic_stromal_lymphopoietin_driven_atopic_inflammation_
L2 - https://doi.org/10.1172/JCI33559
DB - PRIME
DP - Unbound Medicine
ER -